HRA002197
Title:
Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer
Release date:
2022-04-01
Description:
Prostate cancer (PCa) is one of the most prevalent cancers in men worldwide, and hormonal therapy plays a key role in the treatment of PCa. However, the inevitable drug resistance of hormonal therapy makes it urgent and necessary to identify novel targets for PCa treatment. Herein, dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) is found and confirmed to be highly expressed in the PCa tissues and cells, and knock-down of DYRK2 remarkably reduces PCa burden in vitro and in vivo.
Data Accessibility:   
Open access
BioProject:
Study type:
Cell line related study
Dataset Download
MetaData:
Files:
Aspera Command Line:  Help   

 Note: HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client) or Asepra Command Line.

Individuals & samples
Files
Submitter:   Yang Peng / pengyang@cpu.edu.cn
Organization:   China Pharmaceutical University
Submission date:   2022-03-31